MAPK Pathway Inhibitors Augment Treatments for Pediatric Low-Grade Gliomas.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 222
- By:
- Publication type:
- Article
Works matching IS 08909091 AND DT 2023 AND VI 37 AND IP 5
Results: 10
1
2
Lenvatinib Combo Yields Robust, Enduring Responses in Endometrial Cancer.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 221
- Publication type:
- Article
3
Olaparib Plus Selumetinib Shows Benefit in RAS-Mutated Ovarian, Endometrial Cancers.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 221
- Publication type:
- Article
4
Niraparib Yields Limited OS in Final Analysis for Ovarian Cancer.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 220
- Publication type:
- Article
5
RUBY Trial Supports Addition of Dostarlimab to Chemo as SOC in Endometrial Cancer.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 220
- Publication type:
- Article
6
The Complexities and Art of Interpreting Biomarkers and Response to Immune Checkpoint Inhibitors.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 216, doi. 10.46883/2023.25920996
- By:
- Publication type:
- Article
7
An Arthroscopic Approach for the Intralesional Curettage of Giant Cell Tumor of the Distal Femur: A Case Report.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 204, doi. 10.46883/2023.25920994
- By:
- Publication type:
- Article
8
Multidisciplinary Care Is Imperative to the Future of Breast Cancer Treatment.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 202
- By:
- Publication type:
- Article
9
The Painful Problem of Biosimilars in the Clinic.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 200
- By:
- Publication type:
- Article
10
Biomarkers for Response to Anti--PD-1/Anti--PD-L1 Immune Checkpoint Inhibitors: A Large Meta-Analysis.
- Published in:
- Oncology (08909091), 2023, v. 37, n. 5, p. 210, doi. 10.46883/2023.25920995
- By:
- Publication type:
- Article